On September 9, Cooper declined 5.53% in regular trading, trading near $64.00 per share with turnover of approximately $190 million. The sharp sell-off was driven by the company's interim earnings report, which revealed a significant deterioration in profitability.

According to the post-market disclosure, Cooper reported net income attributable to shareholders of $52.9 million for the interim period, representing a steep 72.45% year-over-year decline. Diluted earnings per share came in at just $0.27, a sharp drop from $0.67 in the prior quarter, signaling a pronounced second-fiscal-quarter earnings deterioration. The current stock price has now fallen to approximately the $63 target set by Goldman Sachs, which maintains a Sell rating on the stock. Meanwhile, other major institutions have held more moderate views — Citigroup adjusted its target to $80 with a Neutral rating, UBS initiated coverage at Neutral with a $75 target, and Rothschild & Co Redburn lowered its target to $78 from $85 while maintaining Neutral.

Cooper is a global medical device company operating through CooperVision and CooperSurgical, specializing in contact lenses and fertility and women's health products.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)